E7820 (ER68203-00), an orally active aromatic sulfonamide derivative, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. E7820 inhibits …

E7820 (ER68203-00), an orally active aromatic sulfonamide derivative, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. E7820 inhibits …

2005年6月1日 · E7820 is a potent inhibitor of endothelial cell proliferation and vascular tube formation in vitro, and it effectively inhibits the growth of human breast and pancreatic cancer …

2011年1月1日 · The recommended phase II dose of E7820 is 100 mg/d, based on a fasting schedule. E7820 downregulates integrin α-2 expression in surrogate tissues (platelets) and is …

E7820 is a novel angiogenesis inhibitor, which modulates integrinα2 expression on endothelial cells and shows anti-tumor activity in a variety of xenograft models in nude mice.

E 7820 is a α 2 integrin inhibitor. Inhibits angiogenesis in vitro (IC 50 = 0.11 - 0.25 μM). Also inhibits growth of human colorectal cancer cell lines. Enhances efficacy of erlotinib in a non …

2021年5月18日 · Currently the application of E7820 in the treatment of various malignancies including pancreas carcinoma and breast cancer is being investigated in pre-clinical and …

Synthetic sulfonamide anticancer drugs, including E7820, indisulam, tasisulam, and chloroquinoxaline sulfonamide, exhibit diverse mechanisms of action and therapeutic potential, …

E7820 [N - (3-cyano-4-methyl-1 H -indol-7-yl)-3-cyanobenzene-sulfonamide] is a first-in-class, orally available aromatic sulfonamide derivative that inhibits the proliferation and tube …

Here we report that a novel angiogenesis inhibitor, E7820 (an aromatic sulfonamide derivative), inhibited in vitro proliferation and tube formation of human umbilical vascular endothelial cell …